Genprex Stockholders Approve 1.85M Share Equity Plan Increase and Potential Reverse Stock Split

On June 18, 2026, Genprex, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to adopt the Amended and Restated 2018 Equity Incentive Plan, which increases the number of shares authorized for issuance by 1,850,000 shares and extends the plan's term through April 15, 2036. Additionally, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to authorize a reverse stock split of common stock at a ratio ranging from 1-for-5 to 1-for-50, exercisable at the Board's discretion at any time prior to December 31, 2027. Other matters approved included the election of Jose Antonio Moreno Toscano and Ryan M. Confer as Class III directors to serve until 2029, the ratification of WithumSmith+Brown, PC as the independent accounting firm for the fiscal year ending December 31, 2026, and an advisory vote on executive compensation. The reverse split is intended to provide the Board with flexibility regarding the company's capital structure and Nasdaq listing requirements.